Analysts See $1.25 EPS for Novartis AG (NVS)

April 18, 2018 - By Clifton Ray

Novartis AG (NYSE:NVS) Logo

Analysts expect Novartis AG (NYSE:NVS) to report $1.25 EPS on April, 19 before the open.They anticipate $0.12 EPS change or 10.62 % from last quarter’s $1.13 EPS. NVS’s profit would be $2.93B giving it 16.36 P/E if the $1.25 EPS is correct. After having $1.20 EPS previously, Novartis AG’s analysts see 4.17 % EPS growth. The stock increased 0.75% or $0.61 during the last trading session, reaching $81.78. About 3.10 million shares traded or 75.54% up from the average. Novartis AG (NYSE:NVS) has risen 5.79% since April 18, 2017 and is uptrending. It has underperformed by 5.76% the S&P500.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 4 analysts covering Novartis AG Common Stock (NYSE:NVS), 0 have Buy rating, 2 Sell and 2 Hold. Therefore 0 are positive. Novartis AG Common Stock had 5 analyst reports since October 23, 2017 according to SRatingsIntel. The firm has “Sell” rating given on Wednesday, October 25 by Barclays Capital. Leerink Swann maintained Novartis AG (NYSE:NVS) rating on Thursday, January 25. Leerink Swann has “Market Perform” rating and $100 target. Cowen & Co maintained Novartis AG (NYSE:NVS) on Friday, February 2 with “Hold” rating. Leerink Swann maintained the stock with “Market Perform” rating in Monday, October 23 report. The company was downgraded on Wednesday, December 6 by Bank of America.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $191.96 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 25.16 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

Novartis AG (NYSE:NVS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.